Comparative Pharmacology
Head-to-head clinical analysis: FLAVALTA versus URISPAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAVALTA versus URISPAS.
FLAVALTA vs URISPAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flavoxate is a smooth muscle relaxant with anticholinergic and local anesthetic properties. It inhibits phosphodiesterase, leading to increased cAMP levels, which reduces smooth muscle tone in the urinary tract.
Urispas (flavoxate) is a smooth muscle relaxant that exerts a direct spasmolytic effect on the detrusor muscle of the urinary bladder. It has anticholinergic, local anesthetic, and analgesic properties, but its exact mechanism is not fully understood.
FLAVALTA is not a recognized drug. No data available.
20 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 6.5 hours (range 5.0-8.0 hours), allowing twice-daily dosing in most patients.
Terminal elimination half-life is approximately 2-3 hours in healthy adults; may be prolonged in renal impairment (creatinine clearance <30 mL/min extends half-life to 5-7 hours).
Primarily hepatic metabolism followed by biliary excretion (60-70% as metabolites), renal excretion (20-30% unchanged drug and metabolites), and fecal elimination (5-10%).
Primarily renal (approximately 50-70% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category C
Urinary Antispasmodic
Urinary Antispasmodic